PDS Biotechnology Corporation (FRA:EU6)
Germany
· Delayed Price · Currency is EUR 0.757
+0.034 (4.70%)
At close: Dec 5, 2025
PDS Biotechnology Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Cash & Equivalents | 26.2 | 41.69 | 56.56 | 73.82 | 65.24 | 28.84 | Upgrade
|
| Cash & Short-Term Investments | 26.2 | 41.69 | 56.56 | 73.82 | 65.24 | 28.84 | Upgrade
|
| Cash Growth | -47.34% | -26.29% | -23.38% | 13.15% | 126.23% | 137.13% | Upgrade
|
| Prepaid Expenses | 1.69 | 3.36 | 2.49 | 2.66 | 1.6 | 1.5 | Upgrade
|
| Total Current Assets | 27.89 | 45.05 | 59.06 | 76.48 | 66.84 | 30.34 | Upgrade
|
| Property, Plant & Equipment | 0.26 | 0.3 | 0.34 | 0.53 | 0.36 | 0.55 | Upgrade
|
| Other Long-Term Assets | 6.55 | - | - | - | - | - | Upgrade
|
| Total Assets | 34.71 | 45.36 | 59.39 | 77.01 | 67.2 | 30.89 | Upgrade
|
| Accounts Payable | 5.18 | 1.68 | 6.98 | 1.22 | 1.31 | 1.42 | Upgrade
|
| Accrued Expenses | 2.1 | 2.84 | 2.42 | 8.31 | 2.19 | 1.74 | Upgrade
|
| Short-Term Debt | 6 | 12.5 | 4.17 | - | - | - | Upgrade
|
| Current Portion of Leases | 0.04 | 0.06 | 0.06 | 0.29 | 0.26 | 0.12 | Upgrade
|
| Total Current Liabilities | 13.33 | 17.09 | 13.63 | 9.82 | 3.76 | 3.27 | Upgrade
|
| Long-Term Debt | 11.89 | 9.2 | 19.51 | 23.02 | - | - | Upgrade
|
| Long-Term Leases | 0.03 | 0.06 | 0.12 | 0.16 | 0.23 | 0.49 | Upgrade
|
| Total Liabilities | 25.25 | 26.35 | 33.26 | 33.01 | 3.99 | 3.76 | Upgrade
|
| Common Stock | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 218.48 | 201.1 | 170.62 | 145.55 | 123.9 | 70.91 | Upgrade
|
| Retained Earnings | -209.04 | -182.11 | -144.5 | -101.56 | -60.7 | -43.79 | Upgrade
|
| Shareholders' Equity | 9.45 | 19 | 26.13 | 44 | 63.21 | 27.13 | Upgrade
|
| Total Liabilities & Equity | 34.71 | 45.36 | 59.39 | 77.01 | 67.2 | 30.89 | Upgrade
|
| Total Debt | 17.97 | 21.83 | 23.85 | 23.47 | 0.49 | 0.61 | Upgrade
|
| Net Cash (Debt) | 8.23 | 19.86 | 32.71 | 50.35 | 64.75 | 28.23 | Upgrade
|
| Net Cash Growth | -67.18% | -39.28% | -35.03% | -22.25% | 129.38% | 132.12% | Upgrade
|
| Net Cash Per Share | 0.19 | 0.54 | 1.06 | 1.76 | 2.53 | 1.69 | Upgrade
|
| Filing Date Shares Outstanding | 48.98 | 45.4 | 36.68 | 30.72 | 28.45 | 22.26 | Upgrade
|
| Total Common Shares Outstanding | 47.71 | 37.99 | 33.09 | 30.17 | 28.45 | 22.26 | Upgrade
|
| Working Capital | 14.56 | 27.97 | 45.43 | 66.66 | 63.08 | 27.07 | Upgrade
|
| Book Value Per Share | 0.20 | 0.50 | 0.79 | 1.46 | 2.22 | 1.22 | Upgrade
|
| Tangible Book Value | 9.45 | 19 | 26.13 | 44 | 63.21 | 27.13 | Upgrade
|
| Tangible Book Value Per Share | 0.20 | 0.50 | 0.79 | 1.46 | 2.22 | 1.22 | Upgrade
|
| Machinery | - | 0.3 | 0.27 | 0.12 | 0.12 | 0.12 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.